About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Msh2tm1Htr
targeted mutation 1, Hein Te Riele
MGI:1858055
Summary 13 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
 		Msh2tm1Htr/Msh2tm1Htr either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB) MGI:2183310
hm2
 		Msh2tm1Htr/Msh2tm1Htr involves: 129P2/OlaHsd MGI:4429602
hm3
 		Msh2tm1Htr/Msh2tm1Htr involves: 129P2/OlaHsd * FVB MGI:4429608
ht4
 		Msh2tm1Htr/Msh2+ involves: 129P2/OlaHsd MGI:4429607
cx5
 		Hrhr/Hrhr
Msh2tm1Htr/Msh2tm1Htr 		involves: 129P2/OlaHsd MGI:4429630
cx6
 		Msh2tm1Htr/Msh2tm1Htr
Pcnatm1Jcbs/Pcnatm1Jcbs 		involves: 129P2/OlaHsd MGI:4429640
cx7
 		Htttm5Mem/Htt+
Msh2tm1Htr/Msh2tm1Htr 		involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * CD-1 * FVB/N MGI:4429638
cx8
 		ApcMin/Apc+
Msh2tm1Htr/Msh2tm1Htr 		involves: 129P2/OlaHsd * BALB/c * C57BL/6J MGI:4429611
cx9
 		B4galnt2a/B4galnt2b
Msh2tm1Htr/Msh2tm1Htr 		involves: 129P2/OlaHsd * BALB/c * SWR MGI:4429627
cx10
 		Msh2tm1Htr/Msh2tm1Htr
Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu
Ungtm1Tld/Ungtm1Tld 		involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N MGI:5505262
cx11
 		Msh2tm1Htr/Msh2tm1Htr
Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu
Ungtm1Tld/Ungtm1Tld 		involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N MGI:5507886
cx12
 		Hrhr/Hrhr
Msh2tm1Htr/Msh2tm1Htr
Xpatm1Tnka/Xpatm1Tnka 		involves: 129P2/OlaHsd * C57BL/6 * CBA MGI:4429631
cx13
 		Msh2tm1Htr/Msh2tm1Htr
Tap1tm1Hpl/Tap1tm1Hpl 		involves: 129P2/OlaHsd * FVB MGI:4429609


Genotype
MGI:2183310
hm1
Allelic
Composition		 Msh2tm1Htr/Msh2tm1Htr
Genetic
Background		 either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased T cell derived lymphoma incidence ( J:27469 )
• 30% of homozygous animals developed metastasizing lymphomas of T cell origin, peaking at 2 months of age

endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:27469 )
• 30% of homozygous animals developed metastasizing lymphomas of T cell origin, peaking at 2 months of age

immune system
increased T cell derived lymphoma incidence ( J:27469 )
• 30% of homozygous animals developed metastasizing lymphomas of T cell origin, peaking at 2 months of age

hematopoietic system
increased T cell derived lymphoma incidence ( J:27469 )
• 30% of homozygous animals developed metastasizing lymphomas of T cell origin, peaking at 2 months of age




Genotype
MGI:4429602
hm2
Allelic
Composition		 Msh2tm1Htr/Msh2tm1Htr
Genetic
Background		 involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:45433 )
• two-third of mice die by 19.5 weeks
• Background Sensitivity: mice on a pure 129P2/OlaHsd background die sooner than those on a mixed 129P2/OlaHsd and FVB background

immune system
immune system phenotype ( J:47993 )
N
• somatic hypermutation rates in memory B cells are normal
abnormal class switch recombination ( J:80893 )
• LPS-stimulated blasting B cells exhibit a 7-fold reduction in switching to IgG3 compared with similarly treated wild-type mice
• however, IgM response to LPS treatment is normal
abnormal somatic hypermutation frequency ( J:155454 )
• mice exhibit a 61% reduction in total mutation frequency in germinal center B cell compared with wild-type mice
decreased IgG1 level ( J:80893 )
• following NP-ficcoll or LPS plus IL4 stimulation
decreased IgG3 level ( J:80893 )
• following NP-ficcoll or LPS stimulation
abnormal inflammatory response ( J:80893 )
• LPS-stimulated blasting B cells exhibit a 7-fold reduction in switching to IgG3 compared with similarly treated wild-type mice
• however, the proportion of B cells that blasted in response to LPS is normal

neoplasm
increased tumor incidence ( J:45433 )
• mice that survive beyond 19.5 weeks exhibit a multitude of tumor types (lymphoid, erythroid, intestine, skin, sebaceous gland, brain, intestine, and hereditary nonpolyposis colorectal cancer)
increased gastrointestinal tumor incidence ( J:45433 )
• all mice that survive beyond 30 weeks develop HNPCC (hereditary nonpolyposis colorectal cancer)
increased skin tumor incidence ( J:45433 )
• in mice that survive beyond 19.5 weeks
increased lymphoma incidence ( J:45433 )
• 80% of mice that die prior to 19.5 weeks of age present with a lymphoid tumor, mostly of T cell origin
increased brain tumor incidence ( J:45433 )
• in 13% of mice that survive beyond 19.5 weeks

hematopoietic system
abnormal class switch recombination ( J:80893 )
• LPS-stimulated blasting B cells exhibit a 7-fold reduction in switching to IgG3 compared with similarly treated wild-type mice
• however, IgM response to LPS treatment is normal
abnormal somatic hypermutation frequency ( J:155454 )
• mice exhibit a 61% reduction in total mutation frequency in germinal center B cell compared with wild-type mice
decreased IgG1 level ( J:80893 )
• following NP-ficcoll or LPS plus IL4 stimulation
decreased IgG3 level ( J:80893 )
• following NP-ficcoll or LPS stimulation

integument
increased skin tumor incidence ( J:45433 )
• in mice that survive beyond 19.5 weeks

endocrine/exocrine glands

nervous system
increased brain tumor incidence ( J:45433 )
• in 13% of mice that survive beyond 19.5 weeks

digestive/alimentary system
increased gastrointestinal tumor incidence ( J:45433 )
• all mice that survive beyond 30 weeks develop HNPCC (hereditary nonpolyposis colorectal cancer)

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
Lynch syndrome DOID:3883 OMIM:PS120435
 J:45433




Genotype
MGI:4429608
hm3
Allelic
Composition		 Msh2tm1Htr/Msh2tm1Htr
Genetic
Background		 involves: 129P2/OlaHsd * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:45433 )
• two-third of mice die by 30 weeks
• Background Sensitivity: mice on a mixed 129P2/OlaHsd and FVB background die sooner than those on a pure 129P2/OlaHsd background

neoplasm
increased tumor incidence ( J:45433 )
• mice that survive beyond 30 weeks exhibit a multitude of tumors types (lymphoid, erythroid, intestine, skin, uterus, mammary gland, lung, intestine, sebaceous gland, and hereditary nonpolyposis colorectal cancer)
increased gastrointestinal tumor incidence ( J:45433 )
• 62% of mice that survive beyond 30 weeks develop Hereditary Nonpolyposis Colon Cancer (HNPCC) tumors
increased mammary gland tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks
increased incidence of tumors by chemical induction ( J:45433 )
• all ENU-treated mice develop lymphomas by 14 weeks of age compared with 25% of similarly treated wild-type mice by 13 and 27 weeks
increased skin tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks
increased lymphoma incidence ( J:45433 )
• 80% of mice that die prior to 30 weeks of age present with a lymphoid tumor, mostly of T cell origin
• all ENU-treated mice develop lymphomas by 14 weeks of age compared with 25% of similarly treated wild-type mice by 13 and 27 weeks
increased uterus tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks
increased lung tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

homeostasis/metabolism
increased incidence of tumors by chemical induction ( J:45433 )
• all ENU-treated mice develop lymphomas by 14 weeks of age compared with 25% of similarly treated wild-type mice by 13 and 27 weeks

integument
increased mammary gland tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks
increased skin tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

reproductive system
increased uterus tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

respiratory system
increased lung tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

digestive/alimentary system
increased gastrointestinal tumor incidence ( J:45433 )
• 62% of mice that survive beyond 30 weeks develop Hereditary Nonpolyposis Colon Cancer (HNPCC) tumors

endocrine/exocrine glands
increased mammary gland tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

hematopoietic system

immune system




Genotype
MGI:4429607
ht4
Allelic
Composition		 Msh2tm1Htr/Msh2+
Genetic
Background		 involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:45433 )
• mice die within 100 weeks

neoplasm
increased tumor incidence ( J:45433 )
• mice develop more tumors than wild-type mice including lung, liver, mammary gland, skin, uterus, hemangiosarcoma, Schwann cell, teratocarcinoma, osteosarcoma, adrenal gland, and bladder tumors

integument

liver/biliary system

respiratory system

endocrine/exocrine glands

reproductive system

skeleton




Genotype
MGI:4429630
cx5
Allelic
Composition		 Hrhr/Hrhr
Msh2tm1Htr/Msh2tm1Htr
Genetic
Background		 involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hrhr mutation (18 available); any Hr mutation (87 available)
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
increased mortality induced by ionizing radiation ( J:79734 )
• 20% of mice die 15 weeks after UVB-irradiation unlike similarly treated wild-type mice
premature death ( J:79734 )
• 20% of mice die of lymphomas by 20 weeks of age

neoplasm
increased skin tumor incidence ( J:79734 )
• by 52 weeks, 81% of mice develop skin tumors
• 18 weeks after UVB-irradiation mice develop skin tumors compared with 23 weeks for similarly treated wild-type mice
increased skin papilloma incidence ( J:79734 )
• 23% of spontaneous skin tumors are papillomas
increased skin squamous cell carcinoma incidence ( J:79734 )
• 77% of spontaneous skin tumors are squamous cell carcinomas
increased lymphoma incidence ( J:79734 )
• 20% of mice die of lymphomas by 20 weeks of age
• 15 weeks after UVB-irradiation, mice develop lymphomas unlike similarly treated wild-type mice
increased incidence of tumors by UV-induction ( J:79734 )
• 15 weeks after UVB-irradiation, mice develop lymphomas unlike similarly treated wild-type mice
• 18 weeks after UVB-irradiation mice develop skin tumors compared with 23 weeks for similarly treated wild-type mice
• UVB-irradiated mice do not remain tumor free as long as similarly treated wild-type mice

integument
increased skin tumor incidence ( J:79734 )
• by 52 weeks, 81% of mice develop skin tumors
• 18 weeks after UVB-irradiation mice develop skin tumors compared with 23 weeks for similarly treated wild-type mice
increased skin papilloma incidence ( J:79734 )
• 23% of spontaneous skin tumors are papillomas
increased skin squamous cell carcinoma incidence ( J:79734 )
• 77% of spontaneous skin tumors are squamous cell carcinomas

homeostasis/metabolism
increased mortality induced by ionizing radiation ( J:79734 )
• 20% of mice die 15 weeks after UVB-irradiation unlike similarly treated wild-type mice




Genotype
MGI:4429640
cx6
Allelic
Composition		 Msh2tm1Htr/Msh2tm1Htr
Pcnatm1Jcbs/Pcnatm1Jcbs
Genetic
Background		 involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
Pcnatm1Jcbs mutation (0 available); any Pcna mutation (19 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
abnormal somatic hypermutation frequency ( J:155454 )
• mice exhibit a reduction in total mutation frequency in germinal center B cell compared with wild-type mice that is similar to that observed in Msh2tm1Htr homozygotes

hematopoietic system
abnormal somatic hypermutation frequency ( J:155454 )
• mice exhibit a reduction in total mutation frequency in germinal center B cell compared with wild-type mice that is similar to that observed in Msh2tm1Htr homozygotes




Genotype
MGI:4429638
cx7
Allelic
Composition		 Htttm5Mem/Htt+
Msh2tm1Htr/Msh2tm1Htr
Genetic
Background		 involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * CD-1 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Htttm5Mem mutation (2 available); any Htt mutation (178 available)
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
nervous system
neuronal intranuclear inclusions ( J:81666 )
• intranuclear accumulation of mutant huntingtin is delayed 5 months compared to in Htttm5Mem heterozygotes




Genotype
MGI:4429611
cx8
Allelic
Composition		 ApcMin/Apc+
Msh2tm1Htr/Msh2tm1Htr
Genetic
Background		 involves: 129P2/OlaHsd * BALB/c * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
ApcMin mutation (12 available); any Apc mutation (158 available)
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:45433 )
• survival is reduced 4-fold compared with ApcMin heterozygotes
• all mice die within 5 months

neoplasm
increased gastrointestinal tumor incidence ( J:45433 )
• mice have an 8-fold increase in intestinal tumor load compared with ApcMin heterozygotes

digestive/alimentary system
increased gastrointestinal tumor incidence ( J:45433 )
• mice have an 8-fold increase in intestinal tumor load compared with ApcMin heterozygotes




Genotype
MGI:4429627
cx9
Allelic
Composition		 B4galnt2a/B4galnt2b
Msh2tm1Htr/Msh2tm1Htr
Genetic
Background		 involves: 129P2/OlaHsd * BALB/c * SWR
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
B4galnt2a mutation (0 available); any B4galnt2 mutation (27 available)
B4galnt2b mutation (0 available); any B4galnt2 mutation (27 available)
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
digestive/alimentary system
decreased enterocyte apoptosis ( J:54082 )
• enterocytes of mice treated with MNNG, temozolomide, and cisplatin exhibit reduced apoptosis compared to cells from similarly treated wild-type mice
• decreased induced apoptosis is not affected by O6-benzylguanine treatment

cellular
decreased enterocyte apoptosis ( J:54082 )
• enterocytes of mice treated with MNNG, temozolomide, and cisplatin exhibit reduced apoptosis compared to cells from similarly treated wild-type mice
• decreased induced apoptosis is not affected by O6-benzylguanine treatment




Genotype
MGI:5505262
cx10
Allelic
Composition		 Msh2tm1Htr/Msh2tm1Htr
Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu
Ungtm1Tld/Ungtm1Tld
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
Cell Lines HEPD0529_1_C05
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
Smug1tm1a(EUCOMM)Hmgu mutation (0 available); any Smug1 mutation (14 available)
Ungtm1Tld mutation (0 available); any Ung mutation (24 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:197809 )
• mean life expectancy is 107 days compared with 223 days for Msh2tm1Htr homozygotes
preweaning lethality, incomplete penetrance ( J:197809 )
• fewer than expected mice are identified at weaning

neoplasm
increased tumor incidence ( J:197809 )
• in all mice that die
increased lymphoma incidence ( J:197809 )
• in 4 of 5 mice with tumors




Genotype
MGI:5507886
cx11
Allelic
Composition		 Msh2tm1Htr/Msh2tm1Htr
Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu
Ungtm1Tld/Ungtm1Tld
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
Cell Lines HEPD0529_1_B07
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
Smug1tm1a(EUCOMM)Hmgu mutation (0 available); any Smug1 mutation (14 available)
Ungtm1Tld mutation (0 available); any Ung mutation (24 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:197809 )
• mean life expectancy is 107 days compared with 223 days for Msh2tm1Htr homozygotes
preweaning lethality, incomplete penetrance ( J:197809 )
• fewer than expected mice are identified at weaning

neoplasm
increased tumor incidence ( J:197809 )
• in all mice that die
increased lymphoma incidence ( J:197809 )
• in 4 of 5 mice with tumors




Genotype
MGI:4429631
cx12
Allelic
Composition		 Hrhr/Hrhr
Msh2tm1Htr/Msh2tm1Htr
Xpatm1Tnka/Xpatm1Tnka
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hrhr mutation (18 available); any Hr mutation (87 available)
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
Xpatm1Tnka mutation (0 available); any Xpa mutation (21 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
increased mortality induced by ionizing radiation ( J:79734 )
• 32% of mice die 15 weeks after UVB-irradiation compared with 3% of similarly treated Xpatm1Tnka homozygotes
premature death ( J:79734 )
• 18% of mice die of lymphomas by 20 weeks of age

neoplasm
increased skin tumor incidence ( J:79734 )
• in 81% of mice by 52 weeks
increased skin papilloma incidence ( J:79734 )
• 9% of spontaneous skin tumors are papillomas
increased skin squamous cell carcinoma incidence ( J:79734 )
• 91% of skin tumors are squamous cell carcinomas
• all skin tumors in UVB-treated mice are diagnosed as squamous cell carcinomas
increased lymphoma incidence ( J:79734 )
• 18% of mice die of lymphomas by 20 weeks of age
increased incidence of tumors by UV-induction ( J:79734 )
• UVB-treated mice develop skin tumors a week earlier than similarly treated Xpatm1Tnka homozygotes
• all UVB-treated mice develop skin tumors, all of which are squamous cell carcinomas, at 10 weeks compared with 20 weeks for similarly treated Xpatm1Tnka homozygotes

integument
increased skin tumor incidence ( J:79734 )
• in 81% of mice by 52 weeks
increased skin papilloma incidence ( J:79734 )
• 9% of spontaneous skin tumors are papillomas
increased skin squamous cell carcinoma incidence ( J:79734 )
• 91% of skin tumors are squamous cell carcinomas
• all skin tumors in UVB-treated mice are diagnosed as squamous cell carcinomas

homeostasis/metabolism
increased mortality induced by ionizing radiation ( J:79734 )
• 32% of mice die 15 weeks after UVB-irradiation compared with 3% of similarly treated Xpatm1Tnka homozygotes




Genotype
MGI:4429609
cx13
Allelic
Composition		 Msh2tm1Htr/Msh2tm1Htr
Tap1tm1Hpl/Tap1tm1Hpl
Genetic
Background		 involves: 129P2/OlaHsd * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Msh2tm1Htr mutation (1 available); any Msh2 mutation (95 available)
Tap1tm1Hpl mutation (1 available); any Tap1 mutation (51 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased tumor incidence ( J:45433 )
• mice that survive beyond 30 weeks exhibit a multitude of tumors types (erythroid, intestine, skin, uterus, mammary gland, lung, intestine, and hereditary nonpolyposis colorectal cancer)
increased gastrointestinal tumor incidence ( J:45433 )
• 80% of mice that survive beyond 30 weeks develop Hereditary Nonpolyposis Colon Cancer (HNPCC) tumors
increased mammary gland tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks
increased skin tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks
increased uterus tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks
increased lung tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

integument
increased mammary gland tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks
increased skin tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

reproductive system
increased uterus tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

digestive/alimentary system
increased gastrointestinal tumor incidence ( J:45433 )
• 80% of mice that survive beyond 30 weeks develop Hereditary Nonpolyposis Colon Cancer (HNPCC) tumors

respiratory system
increased lung tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

endocrine/exocrine glands
increased mammary gland tumor incidence ( J:45433 )
• in mice that survive beyond 30 weeks

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
Lynch syndrome DOID:3883 OMIM:PS120435
 J:45433




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory